---
title: "Qulipta (atogepant) in preventive treatment of migraine: Access and coverage questions"
description: "Access and coverage questions on Qulipta (atogepant) in preventive treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cost and coverage, Prior authorization, and Access and support. Questions: Is there a Qulipta savings card (copay card)? How much do patients pay for Qulipta with the savings card? How do patients activate the Qulipta savings card? Can Medicare patients use the Qulipta savings card? 8 further questions follow. 12 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/access-and-coverage"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Qulipta (atogepant) in preventive treatment of migraine: Access and coverage questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Qulipta](https://www.rxabbvie.com/pdf/qulipta_pi.pdf)

## Cost and coverage

<a id="qulipta-savings-card"></a>

### Is there a Qulipta savings card (copay card)?

> “With the QULIPTA Complete Savings Card, eligible commercially insured patients may pay as little as $0<sup>¶</sup> a month
>
> For covered patients
> And while insurance coverage is being established
>
> Card savings are applied to patients’ out-of-pocket costs, including their deductible.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=With%20the%20QULIPTA%20Complete%20Savings,out%2Dof%2Dpocket%20costs%2C%20including%20their%20deductible.)

> “<sup>¶</sup>Eligibility: Available to patients with commercial insurance coverage for QULIPTA who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com or call 1-855-QULIPTA (1-855-785-4782) for more information.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=Available%20to%20patients%20with%20commercial,1%2D855%2DQULIPTA%20%281%2D855%2D785%2D4782%29%20for%20more%20information.)

<a id="qulipta-cost-with-savings-card"></a>

### How much do patients pay for Qulipta with the savings card?

> “97%
>
> of commercially insured patients pay $0<sup>¶</sup>using their QULIPTA Complete Savings Card<sup>3#</sup>”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=97%25,their%20QULIPTA%20Complete%20Savings)

> “<sup>#</sup>Data on File. AbbVie Inc. (Savings card redemption data as of January 2025–December 2025 and subject to change.)”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=on%20File.%20AbbVie%20Inc.%20%28Savings,2025%20and%20subject%20to%20change.%29)

> “<sup>¶</sup>Eligibility: Available to patients with commercial insurance coverage for QULIPTA who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com or call 1-855-QULIPTA (1-855-785-4782) for more information.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=Available%20to%20patients%20with%20commercial,1%2D855%2DQULIPTA%20%281%2D855%2D785%2D4782%29%20for%20more%20information.)

Note: The prior authorization guide on the same site (dated July 2025) states 94%, based on savings card redemption data from January to December 2024. The figure quoted here is from the access and coverage page and uses 2025 data.

<a id="qulipta-savings-card-activation"></a>

### How do patients activate the Qulipta savings card?

> “Activating the Savings Card is simple!
> Scan the QR code or text<sup>†</sup> ENROLL to 785478
> Once activated, patients should download the card to their digital wallet. 
> Patients MUST show their Savings CardEVERY TIME they fill their prescription 
> to save.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 6, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=6)

> “Message and data rates may apply.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 6, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=6)

> “Eligible commercially insured patients 
> may pay as little as $0* a month”

Source: [QULIPTA: prior-authorization-guide.pdf, page 6, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=6)

> “Eligibility: Available to patients with commercial insurance coverage for QULIPTA who meet eligibility criteria. This copay assistance program is  
> not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, 
> Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where  
> prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health 
> insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com or call 1-855-QULIPTA (1-855-785-4782) for additional information.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 6, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=6)

Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links. The second passage begins the footnote marked † in the first, and the last passage is the footnote marked * in the third.

<a id="qulipta-medicare-savings-card"></a>

### Can Medicare patients use the Qulipta savings card?

> “This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=This%20copay%20assistance%20program%20is,or%20where%20prohibited%20by%20law.)

<a id="qulipta-commercial-coverage"></a>

### Is Qulipta covered by commercial insurance?

> “In 2024,<sup>2</sup>
>
> 89% of nationally commercially insured lives had coverage for QULIPTA<sup>‡</sup>
>
> 22<sup>%</sup>
>
> had zero-step coverage<sup>†‡</sup>”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=89%25%20of%20nationally%20commercially%20insured,had%20zero%2Dstep)

> “In 2026,<sup>2</sup>
>
> national commercial coverage for QULIPTA improved to 98%<sup>‡</sup>
>
> 64<sup>%</sup>
>
> had zero-step coverage<sup>†‡</sup>”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=national%20commercial%20coverage%20for%20QULIPTA,had%20zero%2Dstep)

> “<sup>†</sup>Zero-step coverage means the patient does not need to try and fail a prior therapy.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=coverage%20means%20the%20patient%20does,and%20fail%20a%20prior%20therapy.)

> “<sup>‡</sup>AbbVie internal analytics and Managed Markets Insight & Technology, LLC<sup>TM</sup>, a trademark of MMIT. Data as of January 2024 and August 2026 and subject to change.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=internal%20analytics%20and%20Managed%20Markets,2026%20and%20subject%20to%20change.)

> “Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=Data%20are%20not%20a%20guarantee,not%20imply%20efficacy%20or%20safety.)

Note: The QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links states that 98% of nationally commercially insured lives are covered, and its pages 1 and 2 state the share covered with zero steps as 64% (page 1) and 62% (page 2), all with MMIT data as of December 2024. The figures quoted from the access and coverage page give 98% and 64% for 2026 (data as of January 2024 and August 2026); the page was captured on November 14, 2026.

<a id="qulipta-medicare-coverage"></a>

### How many Medicare Part D lives can get Qulipta with no step therapy?

> “Medicare Part D coverage
>
> 60%
>
> of Medicare Part D lives now require zero steps to get QULIPTA<sup>3†§</sup>”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=Medicare%20Part%20D%20coverage,require%20zero%20steps%20to%20get)

> “Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=Data%20are%20not%20a%20guarantee%20of%20coverage%2C%20or%20partial%20or%20full%20payment%2C%20by%20any%20payers%20listed.%20Actual%20benefits%20are%20determined%20by%20respective%20plan%20administrators.%20Insurer%20plans%2C%20coverage%20criteria%2C%20and%20formularies%20are%20subject%20to%20change%20without%20notice.%20Check%20each%20patient%E2%80%99s%20coverage%20with%20applicable%20insurer.%20AbbVie%20does%20not%20endorse%20any%20individual%20plans.%20Formulary%20coverage%20does%20not%20imply%20efficacy%20or%20safety.,-%2AHighest%20Approval%20rates%E2%80%94Source%3A)

> “<sup>†</sup>Zero-step coverage means the patient does not need to try and fail a prior therapy.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=coverage%20means%20the%20patient%20does,and%20fail%20a%20prior%20therapy.)

> “<sup>§</sup>Managed Markets Insight & Technology, LLC<sup>TM</sup>, a trademark of MMIT. Data as of May 2026 and subject to change.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=Markets%20Insight%20%26%20Technology%2C,2026%20and%20subject%20to%20change.)

> “<sup>§</sup>AbbVie internal analytics and Managed Markets Insight & Technology, LLC<sup>TM</sup>, a trademark of MMIT. Data as of January 2026.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=a%20trademark%20of%20MMIT.%20Data%20as%20of%20January%202026.)

Note: The figure carries the marks 3, †, and §. The page prints two footnotes marked §, both quoted here: one below the local coverage lookup (data as of May 2026) and one in the footnote list that follows the Medicare figure (data as of January 2026). The page was captured on November 14, 2026.

## Prior authorization

<a id="qulipta-prior-authorization"></a>

### What are the Qulipta prior authorization requirements?

> “Payers may have varying requirements for patients, which may include:
> •  Being 18 years of age or older
> •  Experiencing a certain number of headache days per month 
>     – For episodic migraine, 4 to 14 headache days per month, with at least 4 of these  
>       being migraine days 
>     – For chronic migraine, at least 15 headache days per month, with at   least 8 of those  
>       being migraine days
> •  Receiving a certain dose strength 
>     – For episodic migraine: 10 mg, 30 mg, or 60 mg taken once daily     
>     – For chronic migraine: 60 mg taken once daily”

Source: [QULIPTA: prior-authorization-guide.pdf, page 5, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=5)

> “Many payers do not require additional clinical tests to support PA criteria.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 5, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=5)

> “Some payers may have quantity limits for QULIPTA®, allowing only a set number of tablets to be 
> prescribed over a predefined time period. 
> Upon PA approval, reauthorization may be required after 12 months.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 5, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=5)

Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links.

<a id="qulipta-pa-continuation-of-therapy"></a>

### How should a Qulipta PA request for continuing therapy be filed?

> “Initial Approval or Continuation of Therapy 
> Designation: If the patient has already 
> received QULIPTA, then request “Continuation of 
> therapy.” Clearly define the patient’s response 
> to therapy”

Source: [QULIPTA: prior-authorization-guide.pdf, page 2, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=2)

Note: The passage is from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links.

<a id="qulipta-step-therapy"></a>

### Does Qulipta require step therapy?

> “Treatment trial, contraindication, or intolerance of 1 to 2 different classes of  
> preventive drugs, such as:
> •	 Antiepileptic drugs (eg, topiramate or gabapentin) 
> •	 Blood pressure drugs/beta blockers (eg, propranolol, atenolol, or metoprolol)
> •	 Antidepressants (eg, amitriptyline or nortriptyline)”

Source: [QULIPTA: prior-authorization-guide.pdf, page 5, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=5)

> “<sup>†</sup>The examples in this section do not represent a complete list of medications that may be required for step therapy by plan administrators.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 5, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=5)

> “In 2026,<sup>2</sup>
>
> national commercial coverage for QULIPTA improved to 98%<sup>‡</sup>
>
> 64<sup>%</sup>
>
> had zero-step coverage<sup>†‡</sup>”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=national%20commercial%20coverage%20for%20QULIPTA,had%20zero%2Dstep)

> “<sup>†</sup>Zero-step coverage means the patient does not need to try and fail a prior therapy.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=coverage%20means%20the%20patient%20does,and%20fail%20a%20prior%20therapy.)

> “<sup>‡</sup>AbbVie internal analytics and Managed Markets Insight & Technology, LLC<sup>TM</sup>, a trademark of MMIT. Data as of January 2024 and August 2026 and subject to change.”

Source: [QULIPTA: Access & Coverage Support for HCPs – QULIPTA® (atogepant), captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/access-and-coverage#:~:text=internal%20analytics%20and%20Managed%20Markets,2026%20and%20subject%20to%20change.)

Note: The QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links states that 98% of nationally commercially insured lives are covered, and its pages 1 and 2 state the share covered with zero steps as 64% (page 1) and 62% (page 2), all with MMIT data as of December 2024. The figures quoted from the access and coverage page give 98% and 64% for 2026 (data as of January 2024 and August 2026); the page was captured on November 14, 2026. The step therapy examples are from page 5 of that guide.

<a id="qulipta-pa-denial-reasons"></a>

### What are common PA denial reasons in the Qulipta prior authorization guide?

> “Most common reasons for PA denial<sup>1</sup>
> •  The patient hasn’t stepped through the required medications	
> •  Questions regarding necessity
> •  Administrative errors
> •  Incomplete information
> •  The requested drug isn’t covered by the patient’s formulary”

Source: [QULIPTA: prior-authorization-guide.pdf, page 7, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=7)

> “When you’re submitting a PA, remember:
> Have your patient’s medical and prescription history and required 
> documentation readily available. Some may be from other providers 
> Carefully review each diagnostic question, as they may vary between payers         
> Ensure the selected ICD-10 or ICD-11 code is accurate and matches other  
> details provided”

Source: [QULIPTA: prior-authorization-guide.pdf, page 7, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=7)

Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links. The guide cites AbbVie data on file (its reference 1) for the denial reasons and does not state that they are specific to QULIPTA.

## Access and support

<a id="qulipta-access-resources"></a>

### What prior authorization and appeal resources does Qulipta offer?

> “Prior Authorization Guide
>
> DOWNLOAD
>
> These are for informational purposes only and are not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage.
>
> Sample Appeals Letter
>
> DOWNLOAD
>
> Letter of Medical Necessity Sample
>
> DOWNLOAD
>
> Formulary Exception Letter”

Source: [QULIPTA: Downloadable Resources – QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/downloadable-resources#:~:text=Prior%20Authorization%20Guide,Formulary%20Exception%20Letter)

> “If you have additional questions, connect with your representative  
> to contact a Field Reimbursement Manager.”

Source: [QULIPTA: prior-authorization-guide.pdf, page 9, captured 2026-11-14](https://www.quliptahcp.com/content/dam/quliptahcp/pdf/prior-authorization-guide.pdf#page=9)

<a id="qulipta-samples"></a>

### Are Qulipta samples available for prescribers?

> “QULIPTA Samples
>
> Get patients started with samples of QULIPTA
>
> ORDER QULIPTA SAMPLES”

Source: [QULIPTA: Downloadable Resources – QULIPTA® (atogepant) HCP, captured 2026-11-14](https://www.quliptahcp.com/support-and-savings/downloadable-resources#:~:text=QULIPTA%20Samples,ORDER%20QULIPTA%20SAMPLES)

Note: The downloadable resources page offered sample ordering when it was captured on November 14, 2026.

## Related pages
- [Medical information: Qulipta (atogepant): Preventive treatment of migraine](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/qulipta--preventive-treatment-of-migraine/storage-and-supply)
